Latest Insider Transactions at Immuneering Corp (IMRX)
This section provides a real-time view of insider transactions for Immuneering Corp (IMRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immuneering Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immuneering Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
400,000
-1.52%
|
$1,200,000
$3.01 P/Share
|
|
Mar 22
2024
|
Thomas J. Schall Director |
BUY
Open market or private purchase
|
Direct |
2,900
+50.0%
|
$5,800
$2.55 P/Share
|
|
Mar 22
2024
|
Harold Eugene Brakewood Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
3,900
+50.0%
|
$7,800
$2.57 P/Share
|
|
Mar 22
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+18.28%
|
$50,000
$2.55 P/Share
|
|
Mar 22
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
393
+4.53%
|
$786
$2.55 P/Share
|
|
Mar 21
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
1,107
+12.31%
|
$2,214
$2.72 P/Share
|
|
Mar 20
2024
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Open market or private purchase
|
Direct |
3,818
+27.57%
|
$7,636
$2.88 P/Share
|
|
Mar 20
2024
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
7,000
+1.98%
|
$14,000
$2.86 P/Share
|
|
Mar 19
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+22.37%
|
$50,000
$2.56 P/Share
|
|
Mar 19
2024
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.87%
|
$40,000
$2.77 P/Share
|
|
Mar 18
2024
|
Ann E Berman Director |
BUY
Open market or private purchase
|
Direct |
57,965
+46.21%
|
$115,930
$2.13 P/Share
|
|
Mar 18
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
50,000
+25.84%
|
$100,000
$2.68 P/Share
|
|
Mar 15
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,344
+39.06%
|
$4,344
$1.62 P/Share
|
|
Mar 15
2024
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+50.0%
|
$6,211
$1.62 P/Share
|
|
Mar 15
2024
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+1.8%
|
$6,211
$1.62 P/Share
|
|
Mar 15
2024
|
Michael Bookman CHIEF LEGAL OFFICER, SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
1,448
+27.33%
|
$1,448
$1.62 P/Share
|
|
Mar 15
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
400,000
-10.82%
|
$800,000
$2.14 P/Share
|
|
Mar 14
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
509,091
-3.13%
|
$2,036,364
$4.71 P/Share
|
|
Dec 22
2022
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.11%
|
$7,500
$3.01 P/Share
|
|
May 25
2022
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
2,551
+0.76%
|
$7,653
$3.92 P/Share
|
|
May 17
2022
|
Michael Bookman CHIEF LEGAL OFFICER, SECRETARY |
BUY
Open market or private purchase
|
Direct |
1,000
+29.39%
|
$4,000
$4.88 P/Share
|
|
May 16
2022
|
Laurie Keating Director |
BUY
Open market or private purchase
|
Direct |
7,000
+33.33%
|
$35,000
$5.0 P/Share
|
|
May 12
2022
|
Biren Amin CFO, TREASURER |
BUY
Open market or private purchase
|
Direct |
1,000
+11.24%
|
$4,000
$4.42 P/Share
|
|
Apr 12
2022
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+0.09%
|
$6,000
$3.01 P/Share
|
|
Mar 23
2022
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+0.13%
|
$24,000
$8.02 P/Share
|
|
Mar 23
2022
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
1,050
+0.32%
|
$7,350
$7.91 P/Share
|
|
Mar 22
2022
|
Scott Barrett CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
900
+10.63%
|
$6,300
$7.49 P/Share
|
|
Mar 15
2022
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
6,667
+36.17%
|
$40,002
$6.75 P/Share
|
|
Mar 15
2022
|
Ann E Berman Director |
BUY
Open market or private purchase
|
Direct |
6,000
+38.71%
|
$36,000
$6.4 P/Share
|
|
Feb 28
2022
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+0.09%
|
$6,000
$3.01 P/Share
|
|
Dec 22
2021
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
322,691
+49.51%
|
-
|
|
Sep 20
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
4,750
+48.23%
|
$114,000
$24.45 P/Share
|
|
Sep 13
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
349
+50.0%
|
$7,329
$21.25 P/Share
|
|
Sep 13
2021
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Indirect |
5,750
+1.44%
|
$120,750
$21.51 P/Share
|
|
Sep 13
2021
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
2,083
+0.08%
|
$45,826
$22.87 P/Share
|
|
Aug 03
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
550,000
+19.62%
|
$8,250,000
$15.0 P/Share
|
|
Aug 03
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,702,628
+50.0%
|
-
|
|
Aug 03
2021
|
Biren Amin CFO, TREASURER |
BUY
Open market or private purchase
|
Direct |
4,175
+37.7%
|
$62,625
$15.0 P/Share
|
|
Aug 03
2021
|
Biren Amin CFO, TREASURER |
BUY
Conversion of derivative security
|
Direct |
2,723
+50.0%
|
-
|
|
Aug 03
2021
|
Scott Barrett CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
667
+9.1%
|
$10,005
$15.0 P/Share
|
|
Aug 03
2021
|
Scott Barrett CHIEF MEDICAL OFFICER |
BUY
Conversion of derivative security
|
Direct |
5,996
+50.0%
|
-
|
|
Aug 03
2021
|
Ann E Berman Director |
BUY
Open market or private purchase
|
Direct |
3,500
+50.0%
|
$52,500
$15.0 P/Share
|
|
Aug 03
2021
|
Michael Bookman CHIEF LEGAL OFFICER, SECRETARY |
BUY
Open market or private purchase
|
Direct |
1,402
+50.0%
|
$21,030
$15.0 P/Share
|
|
Aug 03
2021
|
Robert J Carpenter Director |
BUY
Open market or private purchase
|
Direct |
325,000
+22.05%
|
$4,875,000
$15.0 P/Share
|
|
Aug 03
2021
|
Robert J Carpenter Director |
BUY
Conversion of derivative security
|
Direct |
217,173
+20.86%
|
-
|
|
Aug 03
2021
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
1,353
+17.47%
|
$20,295
$15.0 P/Share
|
|
Aug 03
2021
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Conversion of derivative security
|
Direct |
5,040
+50.0%
|
-
|
|
Aug 03
2021
|
Laurie Keating Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$105,000
$15.0 P/Share
|
|
Aug 03
2021
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
2,098
+0.08%
|
$31,470
$15.0 P/Share
|
|
Aug 03
2021
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
49,099
+1.85%
|
-
|